Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$12.33 - $63.99
Next Earnings Date
May 15 2025
Next Earnings Date
May 15 2025
Latest price
Market Cap | $1.14B |
EV | $448.97M |
Shares Outstanding | 33.90M |
Beta | - |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $26.00 |
P/E 2025E | - |
P/Revenue 2025E | 7.51x |
Revenue | 104.80% |
EPS | - |
Operating Cash Flow | 5.70% |
Free Cash Flow | - |
Revenue | 18.00% |
EPS | 44.50% |
Operating Cash Flow | 20.20% |
Free Cash Flow | 19.80% |
Gross Margin 2025E | 49.00% |
Net Profit Margin 2025E | -355.86% |
ROE 2025E | -24.27% |
ROCE 2024 | -65.92% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
GRAIL, Inc.
GRAL
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ragusa, Robert
Employees
1,000
Website
grail.comIPO Date
2024-06-12
Headquarters
1525 O’Brien Drive, Menlo Park, California, 94025, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved